Malignant Peritoneal and Retroperitoneal Neoplasm

Malignant Peritoneal and Retroperitoneal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

631 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 163
Recruiting: 76
Ph III recruiting: 8
Growth YoY: −39.1%
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (92)

clinicaltrialsPublishedShowing 51–74 of 74 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00652899	Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer	terminated	Phase 2	14	Masonic Cancer Center, University of MinnesotaOTHER	1	Dec 28, 2017	clinicaltrials
NCT00903630	Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	terminated	Phase 1 / Phase 2	15	Masonic Cancer Center, University of MinnesotaOTHER	1